Skip to main content
. 2012 Nov 26;98(1):31–42. doi: 10.1210/jc.2012-2909

Table 2.

TKI-specific monitoring

TKI-specific monitoring Study Frequency
Pazopanib Urinalysis Baseline and periodically
AST (SGPT), ALT (SGOT), bilirubin Baseline and monthly for 4 months
Sunitinib Echocardiogram Baseline and as clinically indicated
Vandetanib Electrocardiograma Baseline, at 2–4 weeks and 8–12 weeks, then every 3 months
a

If any dose reduction or interruption >2 weeks repeat.